Table 2.

Clinical trials of NET inhibitors for COVID-19 Treatment.

NET INHIBITOR	MOLECULAR TARGET/FUNCTION	COVID TRIAL
Pulmozyme (dornase alfa) (126)	Recombinant DNase that improves lung function by thinning sputum.	NCT04359654 NCT04409925
Brensocatib (127)	Inhibits dipeptidyl peptidase 1 and neutrophil proteases	NCT04817332
Anakinra (128)	Interleukin-1 Receptor antagonist	NCT04594356
Glucocorticoid (methylprednisolone) (129)	Immunosuppressive treatment	NCT04244591
Hydroxychloroquine (130)	Reduces activity of immune system by disrupting lysosomal stability	NCT04332991
Colchicine (131)	Anti-inflammatory	NCT04326790
Alvelestat (132)	Neutrophil Elastase inhibitor	NCT00769119